OpGen, Inc. (NASDAQ:OPGN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
“Company”) elected Tina S. Nova, Ph.D. as a member of its Board
of Directors. The Board also confirmed that Dr. Nova is an
independent director. Her term as a director began on April 24,
2017.
experience building and leading novel genomics-based businesses.
She currently serves as president and chief executive officer of
Molecular Stethoscope, Inc., a newly formed molecular diagnostics
company, a position she has held since October 2015. Prior
thereto, she served as senior vice president and general manager
of Illumina’s oncology business unit from July 2014 to August
2015. From March 2000 to April 2014, Dr. Nova was a cofounder and
director, president and chief executive officer of Genoptix
Medical Laboratory, which was purchased by Novartis
Pharmaceuticals Corporation for nearly $0.5 billion in 2011. She
has also held senior executive positions with Nanogen, Inc.,
Ligand Pharmaceuticals, Inc. and Hybritech, Inc. Dr. Nova
currently serves on the board of directors for Arena
Pharmaceuticals, Veracyte, Inc. and is vice chairman of the board
of directors for the newly formed Rady Pediatric Genomics and
Systems Medicine Institute, which is part of Rady Children’s
Hospital-San Diego. She holds a B.S. degree in Biological
Sciences from the University of California, Irvine, and a Ph.D.
in Biochemistry from the University of California, Riverside.
committee.
her Board service as paid by the Company to its non-employee
directors, as disclosed in its filings with the SEC. The Company
also entered into an indemnification agreement with Dr. Nova in
the form previously approved by the Board.
|
Exhibit No.
|
Description
|
|
10.1
|
Form of OpGen, Inc. Indemnification Agreement for Directors
and Executive Officers (incorporated by reference to Exhibit 10.2 to the Company’s Registration Statement on Form S-1, filed with the SEC on March 3, 2015). |
|
10.2
|
OpGen, Inc. Non-Employee Director Compensation Policy
(incorporated by reference to Exhibit 10.16 to the Company’s Registration Statement on Form S-1, Amendment No. 2, filed with the SEC on April 6, 2015). |
About OpGen, Inc. (NASDAQ:OPGN)
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name. OpGen, Inc. (NASDAQ:OPGN) Recent Trading Information
OpGen, Inc. (NASDAQ:OPGN) closed its last trading session down -0.01 at 1.11 with 312,753 shares trading hands.
